within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI01_CeftobiproleMedocaril;

model CeftobiproleMedocaril
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.111111111111111e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.018699999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00959,
    k12 = 2.311111111111111e-06,
    k21 = 2.311111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CeftobiproleMedocaril</td></tr><tr><td>ATC code:</td><td>J01DI01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>18.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ceftobiprole medocaril is a cephalosporin antibiotic prodrug that is rapidly converted in vivo to its active form, ceftobiprole. It is used for the treatment of hospital-acquired and community-acquired pneumonia and has activity against a wide spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved in several countries in Europe and elsewhere, but not currently approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects, with values based on a population pharmacokinetic analysis after intravenous infusion.</p><h4>References</h4><ol><li><p>Torres, A, et al., &amp; Pea, F (2016). Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical pharmacokinetics</i> 55(12) 1507–1520. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0418-z\">10.1007/s40262-016-0418-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27272266/\">https://pubmed.ncbi.nlm.nih.gov/27272266</a></p></li><li><p>Rubino, CM, et al., &amp; Hamed, K (2021). Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. <i>The Pediatric infectious disease journal</i> 40(11) 997–1003. DOI:<a href=\"https://doi.org/10.1097/INF.0000000000003296\">10.1097/INF.0000000000003296</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34533489/\">https://pubmed.ncbi.nlm.nih.gov/34533489</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DI01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CeftobiproleMedocaril;
